Prescription Weight-Loss Medicines
Quick Facts
Who Qualifies for Prescription Weight-Loss Medication?
The National Institute of Diabetes and Digestive and Kidney Diseases explains that prescription weight-management medicines may be considered for adults with obesity or for adults with overweight who also have conditions such as high blood pressure or type 2 diabetes. BMI is a screening measure rather than a complete assessment, so clinicians also consider medical history, current medicines, previous weight-management efforts, pregnancy plans and the potential benefits and harms of each treatment.
Some weight-loss medicines are also authorized for adolescents who meet drug-specific age and weight criteria. Pediatric treatment requires careful assessment of growth, development, mental health and family circumstances. Medication should not be prescribed solely to change appearance, and it does not replace access to nutritious food, physical activity, sleep support or treatment for conditions that can affect weight.
How Do Prescription Weight-Loss Medicines Work?
Semaglutide and liraglutide mimic the gut hormone GLP-1, while tirzepatide activates both GIP and GLP-1 receptors. These injectable medicines can reduce appetite and energy intake and may slow stomach emptying. Other long-term options act through different mechanisms: orlistat reduces fat absorption, naltrexone-bupropion influences appetite-related brain pathways, and phentermine-topiramate combines a sympathomimetic medicine with an antiseizure drug. Setmelanotide is reserved for certain rare, genetically confirmed obesity disorders rather than common obesity.
Response varies substantially among patients. Gastrointestinal symptoms are common with incretin-based treatments, while other medicines have distinct cardiovascular, neurological or psychiatric precautions. Product labeling includes important contraindications and warnings, and some drugs can harm a developing fetus. A clinician or pharmacist should review the full medication list because interactions and overlapping adverse effects can influence which option is safest.
Are Weight-Loss Medicines Intended for Long-Term Treatment?
Obesity is a chronic disease, and weight-regulating biological responses can persist after weight loss. For that reason, the NIH describes long-term medication as a potential component of continuing care rather than a short course. Follow-up should assess weight trajectory, waist-related risk where appropriate, blood pressure, glucose control, adverse effects, nutrition and whether the treatment is improving health and daily functioning.
More weight loss is not automatically better for every patient. Clinicians may adjust the dose, change medicines or discontinue treatment when side effects outweigh benefits or when response is inadequate under the relevant prescribing guidance. Access and affordability also matter: interrupted treatment may contribute to weight regain, and compounded or unapproved products should not be assumed to have the same quality, dosing accuracy or evidence as FDA-approved medicines.
Frequently Asked Questions
No. Prescription medicines are generally used alongside sustainable nutrition, physical activity and behavioral strategies, although care plans should be adapted for disability, illness and individual circumstances.
Weight-loss medicines are not used to promote weight loss during pregnancy, and several must be stopped before a planned pregnancy. Patients should follow the drug-specific label and discuss contraception, pregnancy plans and stopping timelines with their clinician.
Weight regain can occur after treatment ends because appetite and metabolic adaptations may re-emerge. Long-term planning and medical follow-up are therefore important before starting therapy.
References
- National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight & Obesity.
- U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. November 8, 2023.
- U.S. Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. March 8, 2024.